-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Frontline Treatment Options for Higher Risk MDS: Can We Move Past Azacitidine?

Program: Education Program
Session: Are We Personalizing MDS Therapy in 2023?
Hematology Disease Topics & Pathways:
Research, clinical trials, Clinical Research, Combination therapy, Therapies
Saturday, December 9, 2023, 9:30 AM-10:45 AM

David A Sallman, MD

Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL

Disclosures: Sallman: AbbVie, Affimed Gmbh, Gilead, Incyte, Intellisphere, LLC, Molecular Partners AG, PGEN Therapeutics, Inc., Takeda, Zentalis; Advisory board for AvenCell, BlueBird Bio, BMS, Intellia, Jasper Therapeutics, Kite, Magenta Therapeutics, NKARTA, Novartis, Orbita: Consultancy; Aprea, Jazz: Research Funding.

OffLabel Disclosure: venetoclax in MDS

See more of: Are We Personalizing MDS Therapy in 2023?
See more of: Education Program
<< Previous Presentation | Next Presentation